April 3, 2025
StemRIM Inc.

StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans

Osaka, Japan, April 3, 2025 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that a patent has been registered in China for the application related to the novel treatment of traumatic articular cartilage deficiency syndrome, osteoarthritis, and osteochondritis dissecans utilizing the peptide drug developed from the “Regeneration-Inducing Medicine™" development candidate Redasemtide (HMGB1 fragment peptide).

Title of Invention	:	Therapeutic medication for cartilage disorder
Region	:	China
Application No.	:	201980085703.X
Registration No.	:	To be determined
Applicant	:	StemRIM, Osaka University

This patent is intended to expand the indications for Redasemtide, which is currently under development, and we believe that the granting of this patent will ensure the possibility of developing a drug for traumatic articular cartilage deficiency syndrome, osteoarthritis, and osteochondritis dissecans in China.

The pharmaceutical market in China is the second largest in the world, following the United States. Furthermore, driven by demographic changes, the increase in lifestyle-related diseases, and economic growth, the pharmaceutical market in China is expected to continue expanding. As of 2024, the pharmaceutical market is projected to grow from $105 billion to $185 billion-$215 billion by 2028.

In this context, obtaining various patent rights for the "Regeneration-Inducing Medicine™" Redasemtide will broadly ensure the development potential of Redasemtide in China. This will also provide an opportunity to promote the global expansion of "Regeneration-Inducing Medicine™".

The impact on the financial performance for the fiscal year ending July 31, 2025, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely

through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
Twitter: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)